Literature DB >> 12498734

Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms.

Hong-li Jiao1, Bao-lu Zhao.   

Abstract

The aim of this work was to investigate the effects of hypolipidemic agent fenofibrate (FF), a peroxisome proliferator (PP), on human HepG2 cells and to characterize the intracellular events involved. The results showed that, in contrast to the tumor-promoting effects in rodents, high FF concentrations induced human HepG2 cell death through a mechanism involving an increase in the levels of reactive oxygen species (ROS) and intracellular GSH depletion, which led, through mitochondrial dysfunction and perturbation of intracellular Ca(2+) homeostasis, to cell death. The nuclear receptor peroxisome proliferator-activated receptor-alpha (PPAR(alpha)) was expressed following FF treatment. The results suggest that, although long-term administration of PPs causes liver cancer in susceptible species (e.g., rodents), FF inhibits the growth of human HepG2 cells in a dose-related manner and oxidative stress was involved in this effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498734     DOI: 10.1006/taap.2002.9538

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  14 in total

1.  Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis.

Authors:  Keiichirou Morimura; Connie Cheung; Jerrold M Ward; Janardan K Reddy; Frank J Gonzalez
Journal:  Carcinogenesis       Date:  2005-12-24       Impact factor: 4.944

2.  Fenofibrate induces G0/G1 phase arrest by modulating the PPARα/FoxO1/p27 kip pathway in human glioblastoma cells.

Authors:  Dong-feng Han; Jun-xia Zhang; Wen-jin Wei; Tao Tao; Qi Hu; Ying-yi Wang; Xie-feng Wang; Ning Liu; Yong-ping You
Journal:  Tumour Biol       Date:  2015-01-08

3.  Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice.

Authors:  Takero Nakajima; Naoki Tanaka; Gang Li; Rui Hu; Yuji Kamijo; Atsushi Hara; Toshifumi Aoyama
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

4.  ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro.

Authors:  Justyna Drukala; Katarzyna Urbanska; Anna Wilk; Maja Grabacka; Ewa Wybieralska; Luis Del Valle; Zbigniew Madeja; Krzysztof Reiss
Journal:  Mol Cancer       Date:  2010-06-22       Impact factor: 27.401

Review 5.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

Review 6.  Oxygen free radicals and redox biology of organelles.

Authors:  Leni Moldovan; Nicanor I Moldovan
Journal:  Histochem Cell Biol       Date:  2004-09-25       Impact factor: 4.304

7.  Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

Authors:  Kazufumi Dohmen; Toshihiko Mizuta; Makoto Nakamuta; Naoya Shimohashi; Hiromi Ishibashi; Kyosuke Yamamoto
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

8.  Antioxidant and hepatoprotective effects of the red ginseng essential oil in H(2)O(2)-treated hepG2 cells and CCl(4)-treated mice.

Authors:  Min-Ji Bak; Mira Jun; Woo-Sik Jeong
Journal:  Int J Mol Sci       Date:  2012-02-21       Impact factor: 6.208

9.  PPARα, a predictor of patient survival in glioma, inhibits cell growth through the E2F1/miR-19a feedback loop.

Authors:  Yan Shi; Tao Tao; Ning Liu; WenKang Luan; Jin Qian; Rui Li; Qi Hu; Yan Wei; Junxia Zhang; Yongping You
Journal:  Oncotarget       Date:  2016-12-20

10.  Effects of diet-induced obesity on protein expression in insulin signaling pathways of skeletal muscle in male Wistar rats.

Authors:  Sameer Fatani; Abdul-Razak Abubakari; Imose Itua; Christopher Wong; Cecil Thomas; Ebrahim K Naderali
Journal:  Int J Gen Med       Date:  2012-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.